Monday 19 October 2026
Export SSKN’s income statement to Excel — free account
Strata Skin Sciences, Inc.
SSKN Healthcare Medical Devices
Strata Skin Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.7 million, down 8.54% from fiscal 2024. In the quarter to December 2025, revenue fell 2.97%, EPS grew 111.5%, free cash flow fell 376.9% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow SSKN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 4 | 2 | 3 | 6 | 3 | 5 | 5 | 5 | 7 |
P/S ratio |
0.19 | 0.33 | 0.54 | 0.08 | 0.17 | 0.22 | 0.21 | 0.17 | 0.01 | 0.02 |
Altman Z-Score |
(11.48) | (9.53) | (7.68) | (5.60) | (6.00) | (6.05) | (5.52) | (5.26) | (6.62) | (6.25) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.16 | 1.77 | 0.09 | 1.60 |
Altman Z″-Score (non-manufacturers) |
(30.49) | (24.17) | (18.87) | (13.81) | (13.88) | (13.70) | (12.74) | (10.90) | (16.17) | (15.21) |
Beneish M-Score |
(3.33) | (3.93) | (3.91) | (2.45) | (2.69) | (3.48) | (2.95) | (3.09) | (5.51) | (3.02) |
P/Operating CF |
(24.52) | 15.76 | 13.24 | 15.51 | 7.48 | 14.57 | 5.98 | 4.63 | 0.18 | 0.34 |
P/B ratio |
2.02 | 2.23 | 1.43 | 0.13 | 0.20 | 0.19 | 0.23 | 0.16 | 0.02 | 0.03 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.77 | 0.47 | 0.56 | 0.40 | 0.00 | 0.00 |
EV/Sales |
0.87 | 0.54 | 0.76 | 0.11 | 0.00 | (0.46) | (0.01) | (0.13) | 0.21 | 0.65 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 3.19 | 0.00 | 63.89 | 0.00 | 0.00 | 1.15 | 3.68 |
EV/Operating CF |
(9.57) | 96.17 | (49.11) | (4.13) | 0.04 | (5.03) | (0.14) | (1.38) | 1.57 | 62.24 |
EV/FCF |
(6.27) | (12.49) | (4.60) | (0.82) | (0.03) | 60.94 | (0.15) | (1.39) | 1.71 | 67.26 |
Quick Ratio |
0.45 | 1.03 | 1.03 | 0.84 | 1.25 | 1.12 | 1.15 | 2.31 | 0.69 | 1.19 |
Current Ratio |
0.58 | 1.24 | 1.28 | 1.12 | 1.56 | 1.32 | 1.35 | 2.69 | 1.03 | 1.75 |
Net Debt/EBITDA |
(97.86) | (1.74) | (2.70) | 0.87 | 17.74 | 94.45 | (3.51) | (4.13) | 1.09 | 3.60 |
Debt/Assets |
50.29% | 43.50% | 35.81% | 14.98% | 16.39% | 5.40% | 18.30% | 15.57% | 26.17% | 54.39% |
Debt/Equity |
5.28 | 3.06 | 1.19 | 0.36 | 0.30 | 0.10 | 0.30 | 0.24 | 0.52 | 1.60 |
Asset Turnover |
0.94 | 0.87 | 0.71 | 0.73 | 0.64 | 0.49 | 0.67 | 0.69 | 0.77 | 0.66 |
Operating CF/Net income |
0.45 | (0.02) | 0.05 | 0.17 | (0.56) | (0.48) | (0.59) | (0.72) | (0.19) | (0.10) |
Capex/Depreciation |
(0.32) | (0.30) | (0.83) | (0.64) | (0.89) | (0.55) | (0.02) | 0.00 | (0.04) | 0.00 |
Interest Coverage |
(2.40) | (4.39) | (5.25) | (5.02) | (14.02) | (19.32) | (5.84) | (2.94) | (0.56) | (0.73) |
| (158.91%) | (114.22%) | (62.75%) | (23.49%) | (10.55%) | (16.11%) | (12.65%) | (15.78%) | (124.38%) | (21.65%) | |
| (19.13%) | (26.22%) | (22.97%) | (11.23%) | (5.80%) | (9.34%) | (7.99%) | (9.31%) | (52.27%) | (7.15%) | |
ROIC |
(28.40%) | (50.00%) | (27.42%) | (12.71%) | (13.44%) | (24.71%) | (8.67%) | (9.46%) | (4.32%) | (6.56%) |
Return on Tangible Assets |
287.60% | (76.06%) | (71.50%) | (47.94%) | (19.26%) | (38.14%) | (32.99%) | (20.27%) | (269.53%) | (22.54%) |
Average Days of Receivables |
49.00 | 57.13 | 48.58 | 45.13 | 41.80 | 46.54 | 50.68 | 41.48 | 36.09 | 40.30 |
Research and Development Expense of Revenue |
1.37% | 2.63% | 3.95% | 2.85% | 4.78% | 5.52% | 3.17% | 3.57% | 5.39% | 6.28% |
Selling, General and Administrative Expense of Revenue |
75.89% | 69.50% | 70.34% | 70.21% | 76.12% | 73.35% | 70.53% | 65.01% | 59.36% | 64.28% |
Intangible Assets out of Total Assets |
0.16 | 0.19 | 0.33 | 0.50 | 0.41 | 0.32 | 0.35 | 0.39 | 0.53 | 0.51 |
Share Based Compensation of Revenue |
2.09% | 1.27% | 3.91% | 4.05% | 5.48% | 7.07% | 3.78% | 3.03% | 0.59% | 0.37% |
Graham Net Nets |
(2.05) | (1.21) | (0.76) | (5.54) | (0.24) | 0.78 | 0.73 | 1.36 | (24.85) | (37.17) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(111.90%) | (92.44%) | (59.62%) | (193.21%) | (51.20%) | (86.67%) | (61.50%) | (79.19%) | (5,690.48%) | (688.89%) |
Free Cash Flow Yield |
(72.73%) | (13.07%) | (30.50%) | (167.81%) | (42.85%) | (3.43%) | 31.68% | 56.61% | 1,117.08% | 62.50% |
Revenue per Share |
6.60 | 8.82 | 9.55 | 10.42 | 8.80 | 6.87 | 9.88 | 15.24 | 117.03 | 144.91 |
Operating CF per Share |
(0.60) | 0.05 | (0.15) | (0.27) | 0.44 | 0.62 | 0.70 | 1.48 | 15.25 | 1.52 |
Capex per Share |
(0.32) | (0.43) | (1.44) | (1.08) | (1.07) | (0.64) | (0.04) | (0.01) | (1.18) | 0.00 |
Free Cash Flow per Share |
(0.92) | (0.38) | (1.59) | (1.34) | (0.63) | (0.02) | 0.66 | 1.47 | 14.08 | 1.52 |
Cash per Share |
1.70 | 2.26 | 2.32 | 1.96 | 3.70 | 5.39 | 4.89 | 8.42 | 14.99 | 18.54 |
Shareholders Equity per Share |
0.63 | 1.31 | 3.63 | 6.29 | 7.46 | 7.70 | 8.96 | 15.95 | 73.25 | 69.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.63 | 1.31 | 3.63 | 6.29 | 7.46 | 7.70 | 8.96 | 15.95 | 73.25 | 69.46 |
Free Cash Flow |
(4.26) | (1.45) | (5.54) | (4.66) | (2.14) | (0.06) | 2.11 | 2.88 | 3.82 | 0.32 |
Working Capital |
(11.14) | 3.20 | 3.37 | 1.63 | 7.17 | 5.99 | 6.12 | 14.60 | 0.28 | 4.62 |
Capital Expenditures |
(1.47) | (1.64) | (5.02) | (3.74) | (3.65) | (2.16) | (0.11) | (0.01) | (0.32) | (1.01) |
Net Current Asset Value |
(12.01) | (13.36) | (13.78) | (15.39) | (1.21) | 3.95 | 4.87 | 6.95 | (8.50) | (17.72) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.59 | 0.10 | 1.19 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.05 | 0.15 | 0.10 | 0.12 | 0.09 | 0.00 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.52 | 0.54 | 0.51 | 0.59 | 0.60 | 0.71 | 0.93 | 1.05 | 0.97 | 0.89 |
Cash ROIC |
(16.29%) | (5.03%) | (15.45%) | (12.78%) | (4.70%) | (0.14%) | 3.99% | 5.23% | 11.17% | 0.76% |
Accounts Receivable Turnover |
6.55 | 6.93 | 7.49 | 9.15 | 9.40 | 6.30 | 8.12 | 9.14 | 9.73 | 8.23 |
Accounts Payable Turnover |
4.94 | 4.97 | 4.40 | 4.61 | 3.63 | 3.86 | 6.21 | 6.30 | 6.29 | 4.01 |
Inventory Turnover |
5.07 | 5.83 | 5.17 | 4.37 | 2.92 | 2.77 | 3.89 | 4.39 | 4.46 | 3.64 |
Average Days of Payables |
78.55 | 61.93 | 81.91 | 86.86 | 101.71 | 112.65 | 60.64 | 50.56 | 63.94 | 53.53 |
Days of Inventory on Hand |
80.15 | 57.17 | 65.49 | 78.49 | 125.75 | 140.36 | 97.64 | 80.08 | 84.50 | 81.37 |
Average Receivables |
4.69 | 4.85 | 4.46 | 3.95 | 3.19 | 3.67 | 3.89 | 3.27 | 3.27 | 3.73 |
Average Payables |
2.60 | 2.89 | 3.38 | 3.12 | 2.79 | 2.32 | 1.82 | 2.02 | 2.07 | 3.15 |
Average Inventory |
2.53 | 2.46 | 2.88 | 3.29 | 3.47 | 3.24 | 2.91 | 2.90 | 2.91 | 3.47 |
Average Assets |
32.72 | 38.47 | 47.14 | 49.43 | 46.69 | 47.06 | 47.43 | 43.32 | 41.16 | 46.64 |
Average Common Equity |
3.94 | 8.83 | 17.26 | 23.62 | 25.65 | 27.27 | 29.95 | 25.56 | 17.30 | 15.40 |
Columns are period end dates